中方稀土管制效果明显，美企放话：明年我们就会有所作为

Group 1 - The article highlights the increasing pain felt by various industries due to China's rare earth export control measures, prompting foreign manufacturers to accelerate the establishment of their own rare earth supply chains [1][3] - U.S. rare earth manufacturers express confidence in their ability to make significant progress within a year, indicating a strong demand for rare earth resources that have traditionally been supplied by China [1][3] - China controls approximately 70% of global rare earth mining, 85% of refining capacity, and about 90% of rare earth metal alloys and magnet production, showcasing its monopolistic position in the global rare earth processing sector [3] Group 2 - From 2020 to 2023, 70% of U.S. rare earth compounds and metals were imported from China, highlighting the U.S. reliance on Chinese supplies and the determination to reduce this dependency [3] - Some U.S. scholars and media express skepticism about the future of the U.S. rare earth industry, suggesting that the era of U.S. dominance may be coming to an end [3][5] - The U.S. pharmaceutical industry is heavily reliant on China, with over 60% of daily medications and raw materials sourced from China, indicating a significant vulnerability in the U.S. healthcare supply chain [5][7] Group 3 - The article suggests that if the U.S. continues its policies of manufacturing repatriation and tariff threats, it may lead to a situation where American pharmaceutical companies could abandon the U.S. market, resulting in a potential shortage of medications [7] - The actions taken by the U.S. under the Trump administration are portrayed as exposing weaknesses in American hegemony, while China is advised to focus on its own development and respond appropriately to U.S. actions [7]